PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN
Nov 1, 2006, 00:00
10.1016/S1098-3015(10)63452-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)63452-3/fulltext
Title :
PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63452-3&doi=10.1016/S1098-3015(10)63452-3
First page :
Section Title :
Open access? :
No
Section Order :
302